Genzyme Says Work At Allston Plant Will Resume As Planned Later This Month
This article was originally published in The Pink Sheet Daily
Viral contamination in one of the plant's bioreactors caused a complete shutdown, stopping new production of Cerezyme and Fabrazyme.
You may also be interested in...
It's another case where the pandemic spurs adoption of ways to speed the manufacture of vaccines and biologics that have been in development for years.
Emerging global standard could speed testing of biologics and gene therapies for stray viral particles, while sparing laboratory animals.
Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come